Finance

Lists
Why is HUMA down 2.18%?
Dive Deeper
HUMA:NASDAQ
Humacyte Inc
$0.53
-2.18%
(-0.012) 1D
Nov 17, 12:13:21 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HUMA...
Open
$0.54
High
$0.57
Low
$0.52
Mkt. cap
146.90M
Avg. vol.
6.14M
Volume
1.86M
52-wk high
$1.52
52-wk low
$0.34
EPS
-$0.43
Beta
2.64
Shares outstanding
277.80M
No. of employees
184
Open
$0.54
High
$0.57
Low
$0.52
Mkt. cap
146.90M
Avg. vol.
6.14M
Volume
1.86M
52-wk high
$1.52
52-wk low
$0.34
EPS
-$0.43
Beta
2.64
Shares outstanding
277.80M
No. of employees
184
News stories
From web sources and news partners
About Humacyte Inc
CEOLaura Niklason
Employees184
FoundedJan 1, 2004
Headquarters-
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 5 analysts giving stock ratings to HUMA in the past 3 months
Buy
Buy
3
Hold
2
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for HUMA in the last 3 months.
Highest
Current $0.53
$4.00 (+656.86%)
Average
$1.77 (+234.91%)
Lowest
$0.60 (+13.53%)
Analyst
Recommendation
Action
Price target
Projected
Date
Allison Bratzel
Piper Sandler
Hold
Maintained
$1.00
+89.2%
11/16/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$1.25
+136.5%
11/11/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$4.00
+656.9%
11/11/2026
Ryan Zimmerman
BTIG
Buy
Maintained
$2.00
+278.4%
11/10/2026
Christopher Pasquale
Barclays
Hold
Maintained
$0.60
+13.5%
11/11/2026
Matt Miksic
Barclays
Hold
Maintained
$0.50
-5.4%
10/07/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
$2.00
+278.4%
06/01/2026
Last report
Nov 10, 2026
Fiscal period
Q3 2026
-$0.06 / -$0.08
+27.27%beat
Revenue / Est. (USD)
1.03M / 770.00K
+33.51%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
467.00K
495.00K
406.00K
1.03M
Cost of goods sold
23.69M
20.90M
19.38M
1.43M
Cost of revenue
23.69M
20.90M
19.38M
1.43M
Research and development expenses
-
-
-
14.10M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.62M
7.83M
8.03M
9.01M
Operating expense
7.62M
7.83M
8.03M
23.12M
Total operating expenses
31.30M
28.73M
27.40M
24.55M
Operating income
-30.84M
-28.24M
-27.00M
-23.52M
Other non operating income
20.57M
8.52M
-5.16M
6.36M
EBT including unusual items
-24.80M
-17.62M
-36.80M
-15.54M
EBT excluding unusual items
-12.85M
-21.65M
-34.08M
-18.92M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-24.80M
-17.62M
-36.80M
-15.54M
Net profit margin
-5,311.35%
-3,559.39%
-9,064.53%
-1,511.48%
Earnings per share
-0.13
-0.09
-0.16
-0.06
Interest and investment income
503.00K
330.00K
388.00K
601.00K
Interest expense
-3.09M
-2.27M
-2.32M
-2.37M
Net interest expenses
-2.59M
-1.94M
-1.93M
-1.77M
Depreciation and amortization charges
-
-
-
-
EBITDA
-29.05M
-26.44M
-25.21M
-21.79M
Gain or loss from assets sale
5.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps